ARIAD PHARMACEUTICALS INC (ARIA)

US04033A1007

23.99  +0.04 (+0.17%)

After market: 23.98 -0.01 (-0.04%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ARIAD PHARMACEUTICALS INC

NASDAQ:ARIA (2/15/2017, 7:10:00 PM)

After market: 23.98 -0.01 (-0.04%)

23.99

+0.04 (+0.17%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap4.66B
Shares
PEN/A
Fwd PEN/A
Dividend Yield0%
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

ARIA Daily chart

Company Profile

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.

Company Info

ARIAD PHARMACEUTICALS INC

26 LANDSDOWNE ST

CAMBRIDGE MA 02139

P: 617-494-0400

CEO: Paris Panayiotopoulos

ARIA News

News Image4 years ago - BloombergInsider-Trading Tipster Deserves More Than 18 Months, U.S. Says

The son of a pharmaceutical company director who provided secret information to a participant in a global insider-trading network should be sentenced to more than 18 months in prison, U.S. prosecutors told a judge in New York.

News Image4 years ago - InvestorPlace7 Beautiful Biotech Stocks to Buy Here

Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.

News Image4 years ago - BloombergInsider-Trading Witness Gets $10 Million Bail, N.Y. Hotel Room

A Swiss trader who says he raked in $70 million by illegally using secret information from bankers was ordered freed from a New York jail on $10 million bond, after he was the star witness in a trial that shed light on a global insider-trading network.

News Image4 years ago - BloombergGlobal Insider-Trading Probe Lands Conviction of U.S. Leaker

The son of a pharmaceutical-company director was convicted of leaking company secrets to a close friend who prosecutors say was part of a global insider-trading network.

News Image4 years ago - BloombergInsider-Trading Witness Says He Bought ‘Burner’ Phones for Boss

An employee of a New York restaurant owner accused of participating in a global insider-trading network told jurors he bought as many as 10 unregistered “burner” phones for his boss.

News Image4 years ago - BloombergGlobal Insider-Trading Ring Linked to Trial of Pharma CEO’s Son

The criminal trial of a New York man may help explain how tens of millions of dollars in illicit profits were allegedly generated by a global insider-trading network that included a Greek pharmaceutical executive, a Goldman Sachs Group Inc. banker, a Monaco poker player, a Swiss trader and a Manhattan restaurant owner.

ARIA Twits

Here you can normally see the latest stock twits on ARIA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example